| Literature DB >> 35990861 |
Nishat Akbar1, Taha Yaseen1, Arz Muhammad1, Muhammad Danish1, Muhammad Adeel1, Shoaib A Khan1, Hina Ismail1, Kiran Bajaj1, Imdad Ali1, Muhammad Q Panezai1, Munir Tareen1, Abbas A Tasneem1, Syed M Laeeq1, Farina Hanif1, Nasir H Luck1.
Abstract
Introduction: Gallbladder cancer (GBC) is the most common malignant biliary tract tumor with the shortest survival from the time of diagnosis. This poor prognosis is due to the destructive biologic behavior of GBC, lack of sensitive screening tests for early detection, and vague nature of first presentation. Here in this study, we will evaluate the baseline characteristics of the patients presenting with gallbladder carcinoma in our population. Materials and methods: This retrospective study was conducted in the Department of Gastroenterology at Sindh Institute of Urology and Transplantation (SIUT), Karachi. Patient data were compiled and composed from the in-patient health records, radiology, and operational records. Those patients with suspicion of GBC, but negative at histology, or patients having inconclusive radiologic findings, were excluded. Baseline characteristics were recorded. Results were presented as means ± SD for quantitative data or as numbers with percentages for qualitative data. Continuous variables were analyzed using the Student's t-test, while categorical variables were analyzed using the Chi-square test. A p-value of <0.05 was considered statistically significant.Entities:
Keywords: Demographics; Gallbladder; Gallbladder cancer
Year: 2022 PMID: 35990861 PMCID: PMC9357526 DOI: 10.5005/jp-journals-10018-1375
Source DB: PubMed Journal: Euroasian J Hepatogastroenterol ISSN: 2231-5047
Baseline parameters of study population (n = 162)
|
|
|
|---|---|
| Age (years) | 52 ± 12 |
| Hemoglobin (gm/dL) | 10.8 ± 2.0 |
| TLC (109/L) | 13.7 ± 6.9 |
| Platelets (109/L) | 319 ± 153 |
| Total bilirubin (mg/dL) | 10.1 ± 9.5 |
| Direct bilirubin (mg/dL) | 1.01 ± 0.79 |
| Alkaline phosphatase (U/L) | 533 ± 548 |
| Aspartate transaminase (AST) (U/L) | 87 ± 76 |
| Alanine transaminase (ALT) (U/L) | 72 ± 79 |
| Gamma glutamyl transferase (GGT) (U/L) | 316 ± 412 |
| BMI (kg/m2) | 32.4 ± 14.1 |
Frequency of categorical variables of the patients enrolled in the study
|
|
|
|---|---|
| Gender | |
| Male | 61 (37.7) |
| Female | 102 (62.3) |
| Presenting complaint | |
| Jaundice, weight loss, and abdominal pain | 66 (40.7) |
| Abdominal pain only | 37 (22.8) |
| Jaundice only | 33 (20.4) |
| Etiology | |
| Gallstones | 106 (65.4) |
| Carcinogens | 48 (29.7) |
| Others | 8 (4.9) |
| Comorbid illness | |
| Hypertension | 29 (17.9) |
| Diabetes | 15 (9.3) |
| Kidney disease | 3 (1.9) |
| None | 90 (55.6) |
| TNM classification | |
| Stage I | 10 (6.2) |
| Stage II | 50 (30.9) |
| Stage III | 57 (35.2) |
| Stage IV | 45 (27.8) |
| Biopsy | |
| Well-differentiated | 58 |
| Moderately differentiated | 46 |
| Poorly differentiated | 33 |
| Squamous cell carcinoma | 2 |
| Not done | 23 |
| ERCP | |
| Yes | 103 (63.6) |
| No | 59 (34.4) |
| CBD stricture on ERCP | |
| Present | 95 (58.6) |
| Absent | 68 (42.4) |
| PTC | |
| Yes | 9 (5.6) |
| No | 153 (94.4) |
| Treatment | |
| Simple cholecystectomy | 17 (10.5) |
| Extended cholecystectomy | 39 (24.1) |
| Chemotherapy | 14 (8.6) |
| Palliative care | 92 (56.2) |
| Six month mortality | |
| Present | 101 (62.3) |
| Absent | 61 (37.7) |
The baseline characteristics in mortality vs nonmortality group for continuous variables
|
|
|
|
|
|---|---|---|---|
| Age | 51.3 ± 11.6 | 62 ± 12.4 |
|
| Hemoglobin (gm/dL) | 11.5 ± 1.88 | 10.3 ± 2.01 | ≤ |
| TLC (109/L) | 11.26 ± 6.0 | 15.2 ± 7.01 | ≤ |
| Neutrophils (%) | 68 ± 13 | 75 ± 13 | ≤ |
| Lymphocytes (%) | 23 ± 15 | 15 ± 9 | ≤0.001 |
| Platelets (109/L) | 297 ± 137 | 333 ± 161 | 0.148 |
| INR | 1.2 ± 0.8 | 1.8 ± 1.67 |
|
| Urea (mg/dL) | 35 ± 34 | 32 ± 25 | 0.627 |
| Serum creatinine (mg/dL) | 0.9 ± 0.6 | 1.1 ± 1.3 | 0.574 |
| Total bilirubin (mg/dL) | 4.6 ± 7.4 | 13.4 ± 9.1 | ≤ |
| Alkaline phosphatase (U/L) | 336 ± 451 | 652 ± 570 | ≤ |
| Gamma glutamyl transferase (U/L) | 231 ± 454 | 367 ± 378 |
|
| Aspartate transaminase (U/L) | 71 ± 77 | 97 ± 75 |
|
| Alanine transaminase (U/L) | 60 ± 82 | 78 ± 77 |
|
Bold values state that p-values are significant (≤0.001); CBD, common bile duct; ERCP, endoscopic retrograde cholangiopancreatography
Comparison of baseline categorical variables in terms of mortality
|
|
|
|
|
|---|---|---|---|
| Gender | |||
| Male | 34 (55.7) | 27 (26.7) | ≤ |
| Female | 27 (54.3) | 74 (73.3) | |
| Jaundice on presentation | |||
| Yes | 15 (24.5) | 48 (47.5) |
|
| No | 46 (75.5) | 53 (52.5) | |
| Stage of the tumor | |||
| Early (I, II) | 27 (44.3) | 33 (32.6) | 0.139 |
| Advanced (III, IV) | 34 (55.7) | 68 (67.8) | |
| ECOG | |||
| Good | 45 (73.7) | 37 (36.6) | ≤ |
| Poor | 16 (26.3) | 64 (63.4) | |
| Comorbidities | |||
| Present | 36 (59) | 37 (36.6) |
|
| Absent | 26 (41) | 64 (63.4) |
Bold values state that p-values are significant (≤0.001); ECOG, Eastern Cooperative Oncology Group
Multivariate analysis of variables in predicting mortality in patients with gallbladder carcinoma
|
|
|
|
| |
|---|---|---|---|---|
|
|
| |||
| Age | 0.388 | 0.983 | 0.946 | 1.022 |
| Female gender |
| 0.145 | 0.054 | 0.388 |
| Presence of jaundice | 0.897 | 1.073 | 0.370 | 3.1 |
| Hemoglobin | 0.916 | 1.013 | 0.794 | 1.3 |
| TLC |
| 0.905 | 0.82 | 0.991 |
| Neutrophils | 0.498 | 1.018 | 0.96 | 1.072 |
| Leukocytes |
| 1.051 | 1.001 | 1.015 |
| INR | 0.176 | 0.639 | 0.335 | 1.222 |
| Total bilirubin |
| 0.893 | 0.832 | 0.959 |
| Alanine transaminase | 0.317 | 1.003 | 0.997 | 1.01 |
| Alkaline phosphatase | 0.418 | 1.001 | 0.998 | 1.001 |
| Gamma glutamyl transferase | 0.194 | 0.999 | 1.000 | 1.002 |
| ECOG status | 0.12 | 0.455 | 0.167 | 1.238 |
| Presence of comorbid illnesses |
| 0.360 | 0.136 | 0.956 |
Bold values state that p-values are significant (≤0.001); ECOG, Eastern Cooperative Oncology Group